DXNVX, Smooth Progress in Chinese Pharmaceutical Distribution Business..."Antibiotic Demand Up"

DXVX announced on the 23rd that sales of its brand antibiotic Azithromycin are rapidly increasing in China, the world's largest antibiotic pharmaceutical market, and that it is also launching follow-up pharmaceuticals such as arthritis treatment supplements.

DXVX's Chinese subsidiary, Dx&Vx BJ (Beijing DIWEISI Biotechnology Co., Ltd.), supplies Azithromycin antibiotics in China, which are basic pharmaceuticals manufactured by a member company of Sinopharm, China's largest state-owned pharmaceutical group. Recently, demand has surged due to the spread of Mycoplasma infections within China.

Currently, due to the explosive increase in demand for Azithromycin in China, production has continued even during the Chinese holidays in early October. However, they are unable to meet the rapidly growing market demand and are in discussions to expand supply volume.

In addition to antibiotics, Dx&Vx BJ recently launched arthritis supplements and is preparing to sequentially release follow-up pharmaceuticals such as treatments for skin diseases and stomatitis.

A DXVX representative stated, “Due to the recent spread of Mycoplasma pneumonia in China, demand for the treatment Azithromycin has surged, and follow-up pharmaceuticals are being released sequentially. We expect remarkable growth from Dx&Vx BJ, which holds differentiated competitiveness in the Chinese pharmaceutical distribution market.”

This content was produced with the assistance of AI translation services.